Nomination Committee Formed for Spago Nanomedical’s 2026 Annual General Meeting
LUND, Sweden / ACCESS Newswire – December 8, 2025 – Spago Nanomedical AB (STO:SPAGO.ST, FRA:7UX.F) announces that, in line with the AGM’s resolution, a nomination committee for the 2026 AGM has been established.
The committee is constituted by the company’s largest holders as of September 30, 2025, who have indicated their willingness to participate. Together, the committee members represent roughly 60 percent of Spago Nanomedical’s total shares and comprise:
- Peter Lindell, representing Cidro Förvaltning AB along with his personal holding; chair of the Nomination Committee
- Mikael Lönn, representing his personal holding
- Eva Redhe, representing her personal holding
The nomination committee’s mandate is to prepare and present proposals to the AGM concerning the chairman and other directors, as well as the remuneration for each board member. It will also propose the appointment and remuneration of the company’s auditors.
Shareholders wishing to submit proposals to the nomination committee may email [emailprotected]. Proposals must be received no later than January 31, 2026.
For additional information, please contact Mats Hansen, CEO of Spago Nanomedical AB, at +46 46 811 88 or via [emailprotected].
About Spago Nanomedical AB: A Swedish clinical-stage company developing cancer therapies and diagnostics based on a distinctive polymer-based platform designed for more precise treatments and improved disease detection. The company’s shares trade on Nasdaq First North Growth Market (ticker: SPAGO). More information is available at www.spagonanomedical.se. FNCA Sweden AB serves as the company’s Certified Adviser.
Attachments: Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2026 (pr.report/gsrg)
Source: Spago Nanomedical
